NVS vs. CCJ
NVS (Novartis AG) and CCJ (Cameco Corporation) are both stocks. NVS operates in Drug Manufacturers - General (Healthcare), while CCJ operates in Uranium (Energy). Over the past 10 years, NVS returned 10.33%/yr vs 25.85%/yr for CCJ. At a 0.21 correlation, their price movements are largely independent.
Performance
NVS vs. CCJ - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVS achieves a 9.43% return, which is significantly lower than CCJ's 15.25% return. Over the past 10 years, NVS has underperformed CCJ with an annualized return of 10.33%, while CCJ has yielded a comparatively higher 25.85% annualized return.
NVS
- 1D
- -1.84%
- 1M
- 0.27%
- YTD
- 9.43%
- 6M
- 15.91%
- 1Y
- 27.84%
- 3Y*
- 17.18%
- 5Y*
- 13.87%
- 10Y*
- 10.33%
CCJ
- 1D
- 1.93%
- 1M
- -9.69%
- YTD
- 15.25%
- 6M
- 16.00%
- 1Y
- 74.85%
- 3Y*
- 51.07%
- 5Y*
- 37.97%
- 10Y*
- 25.85%
NVS vs. CCJ - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVS Novartis AG | 9.43% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
CCJ Cameco Corporation | 15.25% | 78.38% | 19.47% | 90.49% | 4.35% | 63.19% | 51.47% | -21.08% | 23.58% | -8.20% |
Correlation
The correlation between NVS and CCJ is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.01 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.09 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Nov 8, 1996 | 0.21 |
Over the past year, the correlation between NVS and CCJ has dropped to 0.01 - well below their long-term average of 0.21, suggesting their price drivers have been diverging.
Fundamentals
NVS:
$280.54B
CCJ:
$45.93B
NVS:
$6.99
CCJ:
$1.49
NVS:
20.95
CCJ:
70.56
NVS:
1.42
CCJ:
0.59
NVS:
5.06
CCJ:
12.97
NVS:
7.28
CCJ:
6.49
NVS:
$56.05B
CCJ:
$3.54B
NVS:
$42.19B
CCJ:
$1.04B
NVS:
$22.40B
CCJ:
$996.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVS vs. CCJ — Risk / Return Rank
NVS
CCJ
NVS vs. CCJ - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and Cameco Corporation (CCJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NVS | CCJ | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.01 | ||
| Sortino ratioReturn per unit of downside risk | -0.17 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.25 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 2.21 | 2.93 | -0.72 |
| Martin ratioReturn relative to average drawdown | 5.43 | 6.51 | -1.07 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NVS | CCJ | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.36 | 1.35 | +0.01 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.74 | 0.77 | -0.02 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.53 | 0.56 | -0.03 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.42 | 0.23 | +0.19 |
Drawdowns
NVS vs. CCJ - Drawdown Comparison
The maximum NVS drawdown since its inception was -42.10%, smaller than the maximum CCJ drawdown of -87.53%. Use the drawdown chart below to compare losses from any high point for NVS and CCJ.
Loading charts...
Drawdown Indicators
| NVS | CCJ | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.10% | -87.53% | +45.43% |
Max Drawdown (1Y)Largest decline over 1 year | -12.65% | -25.69% | +13.04% |
Max Drawdown (3Y)Largest decline over 3 years | -19.95% | -40.01% | +20.06% |
Max Drawdown (5Y)Largest decline over 5 years | -20.42% | -40.01% | +19.59% |
Max Drawdown (10Y)Largest decline over 10 years | -26.03% | -57.22% | +31.19% |
Current DrawdownCurrent decline from peak | -10.52% | -21.37% | +10.85% |
Average DrawdownAverage peak-to-trough decline | -10.93% | -46.09% | +35.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.14% | 11.54% | -6.40% |
Volatility
NVS vs. CCJ - Volatility Comparison
The current volatility for Novartis AG (NVS) is 6.16%, while Cameco Corporation (CCJ) has a volatility of 15.98%. This indicates that NVS experiences smaller price fluctuations and is considered to be less risky than CCJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVS | CCJ | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.16% | 15.98% | -9.82% |
Volatility (6M)Calculated over the trailing 6-month period | 14.45% | 39.04% | -24.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.63% | 55.87% | -35.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.85% | 49.87% | -31.02% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 19.62% | 46.69% | -27.07% |
Dividends
NVS vs. CCJ - Dividend Comparison
NVS's dividend yield for the trailing twelve months is around 3.26%, more than CCJ's 0.16% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CCJ Cameco Corporation | 0.16% | 0.19% | 0.22% | 0.20% | 0.39% | 0.29% | 0.46% | 0.67% | 0.53% | 4.33% | 3.82% | 3.24% |
NVS Novartis AG | 3.26% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
NVS vs. CCJ - Financials Comparison
This section allows you to compare key financial metrics between Novartis AG and Cameco Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVS vs. CCJ - Profitability Comparison
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.
CCJ - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported a gross profit of 291.00M and revenue of 847.55M. Therefore, the gross margin over that period was 34.3%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.
CCJ - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported an operating income of 154.28M and revenue of 847.55M, resulting in an operating margin of 18.2%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.
CCJ - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported a net income of 131.09M and revenue of 847.55M, resulting in a net margin of 15.5%.
Frequently Asked Questions
NVS and CCJ have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CCJ has higher volatility (15.98%) compared to NVS (6.16%). In terms of maximum drawdown, NVS dropped -42.10% vs CCJ's -87.53%.
NVS currently has the higher Sharpe Ratio (1.36 vs 1.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVS and CCJ
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer